Across TCGA pan-cancer cohorts, POTEF mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated POTEF data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher POTEF mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated POTEF expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

LUAD, PDAC, and LSCC are the cancer types where POTEF mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	All	0.909	0.622	.025	6	view →
PDAC	DFS	Quartile	III,IV	0.902	0.421	.011	4	view →
LSCC	DFS	Quartile	II,III,IV	0.832	1.000	.032	3	view →
GBM	OS	Quartile	All	0.361	0.572	.031	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: POTEF tumor-vs-normal RNA expression · all POTEF data types